MedTrace Logo

Natural History and Disease Progression Biomarkers of Multiple System Atrophy

NCT04229173 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2023-06-22

No results posted yet for this study

Summary

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease characterised by a variable combination of parkinsonism, cerebellar impairment and autonomic dysfunction. The neuropathological hallmark is the accumulation of alpha-synuclein in oligodendrocytes. While some symptomatic treatments exist, neuroprotective treatments for MSA remain an urgent, unmet need. Moreover, at present there is not a single surrogate biomarker of MSA which could be used to inform clinical trials.

This study seeks to characterise the natural history of MSA on a panel of candidate biomarkers, pre-selected for being putative surrogates of the underlying neurodegenerative process

Conditions

Interventions

DIAGNOSTIC_TEST

MRI acquisition

MRI acquisition

DIAGNOSTIC_TEST

DAT-SPECT

Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)

DIAGNOSTIC_TEST

blood sample, cerebrospinal fluid (optional)

blood sample, cerebrospinal fluid

BEHAVIORAL

Evaluations about motor abilities, depression, cognition and lifestyle

Evaluations about motor abilities (UMSAR scale), depression (BDI scale), cognition (MoCA scale) and lifestyle (MSA- QoL)

BEHAVIORAL

Evaluation about depression cognition

Evaluations about depression (BDI scale), cognition (MoCA scale)

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Olivier RASCOL, MD, PhD · University Hospital, Toulouse

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2022-05-30
Completion
2022-10-28

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04229173 on ClinicalTrials.gov